patritumab
daiichi sankyo
['breast', 'patritumab', 'daiichi']
 2022 updates:
at the asco 2022, presented phase i/ii data of patritumab deruxtecan, in which it showed an encouraging response in her3-expressing metastatic breast cancer or metastatic triple-negative breast cancer. read more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry